Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update
Manfred Kaufmann(Goethe University Frankfurt), Gϋnter von Minckwitz(German Breast group), Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center), William R. Miller(Houston Methodist), Jens‐Uwe Blohmer(Sankt Gertrauden Krankenhaus), Roy E. Smith(Birmingham Women's Hospital), Andreas Makris(Institute of Cancer Research), Vered Stearns(Johns Hopkins University), Raimund Jackesz(Goethe University Frankfurt), Rainer Souchon, Pinuccia Valagussa(Fondazione Michelangelo), Semiglazov Vf(Institute of Oncology NN Petrov), Suzy Scholl(Institut Curie), Sibylle Loibl(Goethe University Frankfurt), Sigfried Seeber(Goethe University Frankfurt), Annette Lebeau(Universität Hamburg), W. Jonat(Goethe University Frankfurt), W. Eiermann(Ludwig-Maximilians-Universität München), Aron Goldhirsch(Istituti di Ricovero e Cura a Carattere Scientifico), Michael Untch(Helios Kliniken)
Cited by 725
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
|Annals of Oncology|2013|3.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k